Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Free Cash Flow: 2019-2024

Historic Free Cash Flow for Day One Biopharmaceuticals (DAWN) over the last 6 years, with Dec 2024 value amounting to -$98.1 million.

  • Day One Biopharmaceuticals' Free Cash Flow fell 105.53% to -$5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$139.2 million, marking a year-over-year decrease of 54.25%. This contributed to the annual value of -$98.1 million for FY2024, which is 33.29% up from last year.
  • As of FY2024, Day One Biopharmaceuticals' Free Cash Flow stood at -$98.1 million, which was up 33.29% from -$147.1 million recorded in FY2023.
  • In the past 5 years, Day One Biopharmaceuticals' Free Cash Flow registered a high of -$13.6 million during FY2020, and its lowest value of -$147.1 million during FY2023.
  • Moreover, its 3-year median value for Free Cash Flow was -$109.9 million (2022), whereas its average is -$118.4 million.
  • In the last 5 years, Day One Biopharmaceuticals' Free Cash Flow tumbled by 257.40% in 2021 and then spiked by 33.29% in 2024.
  • Over the past 5 years, Day One Biopharmaceuticals' Free Cash Flow (Yearly) stood at -$13.6 million in 2020, then slumped by 257.40% to -$48.5 million in 2021, then slumped by 126.42% to -$109.9 million in 2022, then slumped by 33.83% to -$147.1 million in 2023, then spiked by 33.29% to -$98.1 million in 2024.